2025-05-02 09:09:41
Latest Post
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Swastika Investmart Ltd Q4 FY2025 consolidated profit slumps to Rs. 27.17 lakhs
Vertex Securities Ltd consolidated Q4 FY25 loss at Rs. 53.99 lakhs
The Federal Bank Limited consolidated Q4FY25 PAT jumps to Rs. 1108.31 crores
Stock Report
Concord Drugs Ltd Q3 PAT rises on exceptional income of Rs. 3.57 crore
Posted On : 2021-02-14 12:35:11( TIMEZONE : IST )
Concord Drugs Ltd has reported financial results for the period ended December 31, 2020.
Financial Results (Q3 FY20-21) - QoQ Comparison
The company has reported total income of Rs.8.24 crores during the period ended December 31, 2020 as compared to Rs.16.61 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.2.69 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.0.0807 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.3.09 for the period ended December 31, 2020 as compared to Rs.0.09 for the period ended September 30, 2020.
| Financials | Q3 FY20-21 | Q2 FY20-21 | % Change |
| Total Income | ₹ 8.24 crs | ₹ 16.61 crs |  -50.39% |
| Net Profit | ₹ 2.69 crs | ₹ 0.0807 crs |  3233.33% |
| EPS | ₹ 3.09 | ₹ 0.09 | 3333.33% |
Financial Results (Q3 FY20-21) - YoY Comparison
The company has reported total income of Rs.8.24 crores during the period ended December 31, 2020 as compared to Rs.10.92 crores during the period ended December 31, 2019.
The company has posted net profit / (loss) of Rs.2.69 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.0.0443 crores for the period ended December 31, 2019.
The company has reported EPS of Rs.3.09 for the period ended December 31, 2020 as compared to Rs.0.05 for the period ended December 31, 2019.
| Financials | Q3 FY20-21 | Q3 FY19-20 | % Change |
| Total Income | ₹ 8.24 crs | ₹ 10.92 crs | -24.54% |
| Net Profit | ₹ 2.69 crs | ₹ 0.0443 crs | 5972.23% |
| EPS | ₹ 3.09 | ₹ 0.05 | 6080% |
Financial Results (9 Months ended FY 20-21) - YoY Comparison
The company has reported total income of Rs.43.08 crores during the 9 months period ended December 31, 2020 as compared to Rs.38.38 crores during the 9 months period ended December 31, 2019.
The company has posted net profit / (loss) of Rs.2.94 crores for the 9 months period ended December 31, 2020 as against net profit / (loss) of Rs.0.2351 crores for the 9 months period ended December 31, 2019.
The company has reported EPS of Rs.3.37 for the 9 months period ended December 31, 2020 as compared to Rs.0.27 for the 9 months period ended December 31, 2019.
| Financials | 9 Months ended FY20-21 | 9 Months ended FY19-20 | % Change |
| Total Income | ₹ 43.08 crs | ₹ 38.38 crs | 12.25% |
| Net Profit | ₹ 2.94 crs | ₹ 0.2351 crs | 1150.53% |
| EPS | ₹ 3.37 | ₹0.27 | 1148.15% |
Shares of Concord Drugs Ltd was last trading in BSE at Rs.25 as compared to the previous close of Rs. 24.75. The total number of shares traded during the day was 4604 in over 30 trades.
The stock hit an intraday high of Rs. 25 and intraday low of 23.6. The net turnover during the day was Rs. 109441.
